Affinity Asset Advisors’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-125,969
| Closed | -$1.54M | – | 96 |
|
|
2023
Q4 | $1.54M | Sell |
125,969
-152,323
| -55% | -$1.87M | 0.28% | 53 |
|
|
2023
Q3 | $2.68M | Buy |
278,292
+100,000
| +56% | +$963K | 0.75% | 33 |
|
|
2023
Q2 | $1.6M | Sell |
178,292
-30,000
| -14% | -$270K | 0.56% | 36 |
|
|
2023
Q1 | $1.64M | Buy |
208,292
+20,000
| +11% | +$157K | 0.54% | 39 |
|
|
2022
Q4 | $1.27M | Buy |
188,292
+91,974
| +95% | +$622K | 0.5% | 39 |
|
|
2022
Q3 | $1.4M | Buy |
+96,318
| New | +$1.4M | 0.39% | 35 |
|
|
2021
Q3 | – | Sell |
-50,000
| Closed | -$1.2M | – | 79 |
|
|
2021
Q2 | $1.2M | Sell |
50,000
-50,000
| -50% | -$1.2M | 0.43% | 42 |
|
|
2021
Q1 | $2.57M | Buy |
100,000
+55,000
| +122% | +$1.41M | 0.87% | 27 |
|
|
2020
Q4 | $855K | Buy |
+45,000
| New | +$855K | 0.45% | 41 |
|